Background International consensus recognises four medulloblastoma molecular subgroups: WNT (MB WNT ), SHH (MB SHH ), group 3 (MB Grp3 ), and group 4 (MB Grp4 ), each defined by their characteristic genome-wide transcriptomic and DNA methylomic profiles. These subgroups have distinct clinicopathological and molecular features, and underpin current disease subclassification and initial subgroup-directed therapies that are underway in clinical trials. However, substantial biological heterogeneity and differences in survival are apparent within each subgroup, which remain to be resolved. We aimed to investigate whether additional molecular subgroups exist within childhood medulloblastoma and whether these could be used to improve disease subclassification and prognosis predictions.
Introduction
The discovery of molecular disease subgroups represents the most fundamental advance in our understanding of medulloblastoma, the most common malignant brain tumour of childhood. Current international consensus recognises four subgroups of medulloblastoma: WNT (MB WNT ), SHH (MB SHH ), group 3 (MB Grp3 ) and group 4 (MB Grp4 ). 1 Each subgroup is defined empirically by genome-wide transcriptomic [2] [3] [4] [5] [6] and DNA methylation patterns 7, 8 and characterised by distinct clinicopathological and molecular features. [9] [10] [11] [12] MB WNT and MB SHH are synonymous with WNT and SHH activating mutations. 12 By contrast, MB Grp3 and MB Grp4 have few mutations, but have multiple DNA copy number alterations. [9] [10] [11] [12] Subgrouping is integral to the 2016 WHO medulloblastoma classification, 13 and is used to direct treatment strategies aimed at improving cure rates (5-year survival across all four subgroups is 65-70%), and reducing long-term intellectual and neuroendocrine impairments associated with existing multimodality therapies. Patients with childhood MB WNT consistently show a favourable prognosis (>90% survival 14, 15 ) and reduced intensity risk-adapted therapies are being studied in these patients in international clinical trials, 16 whereas SHH pathway inhibitors show promise in MB SHH disease in early-phase trials, 17 although treatment of infants (younger than 3 years at diagnosis) and young children with these inhibitors should be approached with caution, because of the risk of premature fusion of growth-plates. 18 Substantial biological heterogeneity is evident within each non-MB WNT subgroup; for instance, TP53 mutations are associated with a poor outcome in MB SHH . 13, 19 Highrisk clinical factors (metastatic disease [M+] ; large-cell, anaplastic [LCA] pathology; incomplete surgical resection [R+] ; and MYC/MYCN amplification), which are currently used to stratify risk in medulloblastoma in children aged 3 years or older, were derived from cohortwide investigations before discovery of the consensus subgroups, and thus did not consider their effect. 15, 16, 20, 21 Studies that defined the four-subgroup consensus used modestly sized cohorts (typically fewer than 200 patients). [2] [3] [4] [5] [6] In this Article, we describe comprehensive molecular profiling of clinically annotated discovery and validation cohorts totalling more than 700 tumours.
We report the discovery and characterisation of seven stable and reproducible primary subgroups of childhood medulloblastoma (in patients younger than 16 years at diagnosis), which subdivide each of the classic consensus non-MB WNT subgroups (MB SHH , MB Grp3, and MB Grp4 ) into two clinically significant groups with distinct clinicomolecular features and survival outcomes.
Methods

Study design and participants
In this retrospective cohort study, we assessed 428 centrally reviewed, clinically annotated primary medulloblastomas from patients aged 0-16 years at diagnosis, collected from UK Children's Cancer and Leukaemia Group (CCLG) treatment centres (UK; 366 [86%]), collaborating European institutions in Budapest (Hungary; 20 [5%]) and Warsaw (Poland; 15 [4%]), and samples from the European UKCCSG-SIOP-PNET3 clinical trial (27 [6%] ). As is typical for medulloblastoma, we regarded patients younger than 3 years at diagnosis as infants. 108 (26%) of 408 patient samples used were collected in 2010- 14, 192 (47%) in 2000-10, 85 (21%) in 1990-2000, and the remaining 23 (6%) were collected before 1990 (18 were from the 1980s, four from the 1970s, and one was from 1968). Year of diagnosis was unavailable for 20 samples.
Tumour samples were provided by the UK CCLG as part of CCLG-approved biological study BS-2007-04; informed, written consent was obtained from parents of all patients because all assessed patients were younger than 16 years. Tumour investigations were done with
Research in context
Evidence before this study The international consensus definition of medulloblastoma, published in 2012, recognises four primary molecular subgroups with distinct clinicopathological features: WNT (MB WNT ), SHH (MB SHH ), group 3 (MB Grp3 ), and group 4 (MB Grp4 ). Several studies established characteristic genome-wide transcriptomic and DNA methylomic profiles, using unsupervised class discovery techniques, which defined the consensus subgroups. These subgroups, described in the 2016 WHO classification of brain tumours, underpin current disease subclassification, research studies, and clinical trials. Profiling and class discovery studies published to date in medulloblastoma are based on cohorts typically with sample sizes less than 200 patients and, even within the consensus subgroups, significant heterogeneity of clinical and molecular features remains and many relationships to disease outcome are unresolved. Evidence from the component studies and reviews undertaken in the international consensus definition and the 2016 WHO classification, alongside our own reviews of the current literature, formed the foundation for the present study; no systematic reviews were carried out.
Added value of this study
We defined and characterised seven robust, reproducible, clinically significant, primary molecular subgroups within childhood medulloblastoma (in children aged up to 16 years at diagnosis), each with distinct clinicomolecular features. We propose a cross-validated, subgroup-dependent survival model that incorporates these novel subgroups, alongside established disease features and risk-factors and outperforms the disease risk-stratification schemes in current clinical use. Redistribution of disease risk using this scheme identifies substantial proportions of favourable-risk non-infant patients (>90% 5-year survival in 11% of patients) outside the MB WNT subgroup (equivalent to approximately 70 patients per year in the European Union [EU]) who would be suitable for consideration of reduced intensity of therapy, and very-high-risk non-infant patients (<40% survival, 13% of patients, about 80 EU patients per year) for whom new treatment strategies should be prioritised.
Implications of all the available evidence
These data provide a step-change in our understanding and characterisation of molecular subgroups within medulloblastoma, with potential application to future disease subclassification, risk-stratification, and subgroup-dependent translational research.
approval from Newcastle North Tyneside Research Ethics Committee (study reference 07/Q0905/71); all tumour material was collected in accordance with this approval. We used 276 medulloblastomas (GSE54880) from a published tumour archive, 8 comprising patients aged from 0-18 years at diagnosis, as an independent validation cohort. 18 post-mortem cerebellar samples were collected from the Newcastle Brain Tissue Resource and used as controls in some analyses; all samples were collected with written, informed consent.
Procedures
We tested medulloblastoma samples with the Illumina HumanMethylation450K DNA methylation array (Illumina, San Diego, CA, USA). The Gene Expression Omnibus accession number for 450K DNA methylation array profiles we used for the determination of human medulloblastoma molecular subgroup status is GSE93646.
To identify methylation-dependent subgroups, we did unsupervised class discovery by NMF-metagene and k-means clustering, testing all combinations of 3-10 metagenes and clusters for reproducibility using bootstrapped resampling methods (250 iterations) as described previously. 7 This analysis identified metagenes (a single score that reflects the methylation status of several CpG loci) representing the main biological effects present in the genome-wide dataset. We assessed cluster stability using the cophenetic index, a shorthand measure of the robustness of sample clustering as determined by consensus non-negative matrix factorisation (appendix p 3). We visualised clusters with t-SNE. 22 We assigned samples classified with less than 80% confidence (by resampling procedures) as non-classifiable (NC; appendix pp 2-3).
We projected metagenes derived from our discovery cohort onto the validation cohort. Additionally, we combined the discovery and validation cohorts to do equivalent consensus clustering.
We assessed established medulloblastoma clinical, pathological, and molecular features as described previously. 7 Briefly, we defined histopathological variants according to the WHO 2016 guidelines. 13 We assigned metastatic status (M+) based on Chang's criteria (appendix p 3). Tumours were designated as R+ if their residuum after surgical excision exceeded 1·5 cm². Pathology was centrally reviewed by three experienced neuropathologists for 380 (89%) of 428 samples, and clinical data were collated from contributing centres and reviewed centrally (appendix p 3). We assessed MYC and MYCN status by fluorescence in situ hybridisation or copy-number estimates from methylation array. We assessed TP53, CTNNB1, and TERT mutation status by Sanger sequencing. We identified subgroup-specific differentially methylated CpG loci or methylated regions (DMRs) using limma or DMRcate 23, 24 (appendix p 3). RNA-seq expression data were generated for discovery cohort samples for which mRNA of sufficient quantity and quality was available. We identified subgroupspecific differentially expressed genes using DESeq2, 25 and these genes were included in ontology enrichment analyses (appendix p 4). We identified GFI1 mutations from RNA-seq data (appendix p 4).
MB SHH mutation data were obtained from a previous study. 26 Although 450K methylation data for MB SHH subgroup assignment were not available for this sample cohort, the tightly defined age cutoff that we defined between the molecularly determined MB SHH-Infant and MB SHH-Child subgroups enabled us to infer subgroups for this sequencing cohort (appendix p 4). 26 We tested recurrent MB SHH mutations (TP53, SUFU, PTCH1, SMO, and TERT) and gene amplifications (MYCN and GLI2) identified by whole genome sequencing, for association with the age-defined MB SHH-Child or MB SHH-Infant subgroups using Fisher's exact test (appendix p 4).
Statistical analysis
We did survival analyses (overall survival and progressionfree survival) on samples from patients aged 3-16 years within our discovery cohort, who received maximal surgical resection and craniospinal irradiation with curative intent. Overall survival was defined as the time from date of surgery to death or date of last follow-up and progression-free survival as the time from date of surgery to first event (progression or relapse) or date of last follow-up. Patients with follow-up time that exceeded 10 years were right-censored at 10 years.
The tightly defined age cutoff between the molecularly determined MB SHH-Infant and MB SHH-Child subgroups enabled us to assess an expanded survival cohort of MB SHH-Child disease (n=55), including additional samples with insufficient DNA for methylation array analysis, classified as MB SHH-Child on the basis of their age (appendix p 4). In this group, we assessed the prognostic potential of currently used clinical and molecular risk markers (M+ disease, R+ disease, LCA pathology, sex, MYCN amplification, TERT mutation, and TP53 mutation [appendix pp [4] [5] ). Patients in the MB SHH-Infant subgroup were typically younger than 3 years at diagnosis and were, therefore, treated on infant protocols. Treatment in this group of patients is heterogeneous, and is focused on omitting or delaying radiotherapy to reduce treatment-associated morbidities as far as possible. As a consequence, we report only overall survival in this group.
We created univariate and cross-validated multivariate Cox models based on subgroups, established risk factors, and cytogenetic changes. Prognostic markers in the multivariate analysis were identified by performing 100 rounds of 10-fold cross-validation, evaluating the performance of markers by measuring area under the curve (AUC) at 5 years for progression-free survival in the left out fold, and calculating the overall mean AUC over all rounds (appendix p 5). We added variables conferring an increase in AUC, as measured by time-dependent receiver operating characteristic curves at 5 years, to the model.
See Online for appendix
Because MB Grp3 and MB Grp4 shared a metagene (V1), which defined a low-risk outcome and implied shared biology, we considered MB Grp3/4 as a single entity, and MB Grp3 and MB Grp4 separately for creation of survival models. Ixdition to currently understood clinical and molecular risk markers in these groups (M+ disease, R+ disease, LCA pathology, gender, MYC/MYCN amplification, and i17q [isochromosome 17q]), we additionally tested for recurrent cytogenetic changes, MB Grp3 membership, and membership of the high-risk methylomic group composed of members from both MB Grp3 and MB Grp4 , defined by metagene V1 (appendix pp 5-6). We categorised identified independent prognostic markers into risk-stratification schemes (favourable-risk, >90% survival; standard-risk, >75-90% survival; high-risk, 40-75% survival; very highrisk, <40% survival) and survival-dependent ROC analysis of progression-free survival at 5 years, to assess performance 27 by comparison with previously reported classification schemes (appendix pp 5-6). 16, 28 We constructed Kaplan-Meier curves and compared patient groups with log-rank tests. For Kaplan-Meier comparison of two groups, we calculated hazard ratios (HRs) for the 0-5 year survival interval and 95% CIs from the Wald statistic. We tested the proportionality assumption for Cox modelling using scaled Schoenfeld residuals. Missing data were assumed to be missing completely at random and affected samples were removed from multivariate analyses. We implemented array processing, normalisation, quality-control checks, and copy-number estimation, relative to a panel of 18 normal cerebella with the R packages minfi 29 and conumee (appendix p 2).
The significance threshold was set at p<0·05 for all statistical tests in this study, unless otherwise stated. Significance of association was assessed using Fisher's exact and chi-squared tests with Yates' continuity correction. We identified subgroup-specific age-differences between the non-MB WNT or non-MB SHH medulloblastoma subgroups using ANOVA (appendix p 4). Statistical or bioinformatics analyses were done using R (version 3.2.3).
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all of the data and had the final responsibility to submit for publication.
Results
Clinicopathological and molecular diagnostic characteristics of 428 patients younger than 16 years who had primary childhood medulloblastoma (discovery cohort) are shown in figure 1C, 1D ).
Clinicopathological and biological features were nonrandomly distributed in all seven subgroups (figure 1A, appendix pp 12-15). Patients in the MB SHH-Infant subgroup had significantly enriched desmoplastic or nodular pathology compared with all other subgroups (p<0·0001), and TP53 mutation (p<0·0001) and MYCN amplifications (p<0·0001) were significantly more frequent in MB SHH-Child than in all other subgroups. Patients in the MB Grp3-HR subgroup significantly more frequently had LCA pathology (p<0·0001) and MYC amplification (p<0·0001), than all other subgroups. Although patients in the MB Grp3-HR and MB Grp4-HR subgroups had similar 10-year overall survival (22% [95% CI 10- Validation by projection of six metagenes onto an independent cohort 8 of 276 patients (table 1) confirmed their existence (appendix pp 10-11). Moreover, reapplying consensus clustering to the combined cohort of 704 patients confirmed a seven subgroup model as optimal, giving 100% concordance to the classifications derived separately from our discovery cohort (appendix pp [10] [11] .
Age distributions differed between the two MB SHH subgroups; age distributions are log-normally distributed and intersect at 4·3 years (figure 2A). The two peak incidences of age at diagnosis in infants and in older children for MB SHH disease, 26 when observed as a whole, are resolved by their classification into distinct MB SHH-Infant and MB SHH-Child subgroups (appendix pp 12-13). Each MB SHH subgroup possesses characteristic molecular or clinicopathological features (appendix pp 12-13). LCA pathology (p=0·00050), MYCN amplification (p<0·0001), and mutations of TP53 (p<0·0001) and TERT (p=0·0015) were all significantly enriched in the MB SHH-Child subgroup compared with the MB SHH-Infant subgroup; whereas gender, M+ disease status, and R+ disease status were not significantly different between groups (figure 2B; appendix pp 12-13). TERT promoter mutation and MYCN amplification or LCA pathology were mutually exclusive (figure 2B; appendix pp 12-13). Mutational data from an independent MB SHH cohort 26 showed that SUFU mutation was significantly associated with MB SHH-Infant , whereas PTCH1 mutations were observed in both MB SHH subgroups ( figure 2C ). GLI2 amplification, MYCN amplification, and TP53 mutations (both somatic and germline) were significantly associated with the MB SHH-Child subgroup (figure 2C).
Compared with normal cerebella and patients in the MB SHH-Infant subgroup, patients in the MB SHH-Child subgroup had subgroup-specific DNA methylation changes (0) 22 (7) 53 (6) 27 (10) 34 (11) 17 (9) 54 (16) 25 (8) 18 (11) 34 (18) 23 (12) 30 (12) 10 (13) 36 (26) 16 (9) 7 (20) (0) 18 (8) 40 (9) 8 (4) 4 (3) 14 (7) 37 (15) 16 (8) 12 (12) 29 (17) 6 (5) 3 (3) 8 (10) 22 (21) 11 (9) 6 (18) 20 (26) 4 (7) 2 (4) 8 (10) 13 (25) 8 (12) 4 (20) The age distributions of patients in the four MB Grp3 and MB Grp4 subgroups differed significantly (p<0·0001). Patients in the MB Grp3-LR and MB Grp3-HR subgroups were younger at diagnosis than those in the MB Grp4-LR and MB Grp4-HR subgroups (appendix pp [14] [15] figure 3A .
Several hundred differentially methylated CpG probes or regions defined the four subgroups. MB Grp3-HR was characterised by the greatest number of significantly differentially methylated CpGs compared with other subgroups, commonly hypomethylated CpG loci ( figure 3B; appendix pp 14-15) . Notably, the low-risk subgroups were defined primarily by hypermethylation with respect to normal cerebellum, whereas the high-risk subgroups were defined by hypomethylation ( figure 3B ; appendix pp [14] [15] . Cytogenetic changes distinguished each subgroup as unique from the others ( figure 3C ). These distinguishing cytogenetic features were validated in an independent cohort (appendix pp [14] [15] .
We did survival analyses in an MB SHH-Child cohort that included 31 additional SHH cases unsuitable for 450k array analysis and classified as MB SHH-Child on the basis of age (appendix pp [4] [5] . In this cohort, one out of three assessable TP53 mutations were germline (appendix pp [16] [17] . TP53 mutation was significantly associated with MYCN amplification (p=0·022) and LCA pathology (p=0·0033), MYCN amplification was associated with LCA pathology (p<0·0001), and LCA pathology and MYCN amplification were never observed with TERT mutations (p=0·00079 for LCA and p=0·0090 for MYCN amplification). There was no significant association between metastatic (M+) disease and TP53 mutation (p=1), MYCN amplification (p=0.15), or LCA pathology (p=0·67), or an association between subtotally resected (R+) disease and TP53 mutation (p=1), MYCN amplification (p=1) or LCA pathology (p=0·41). Univariate survival analysis of clinicobiological features (including risk features established in disease-wide studies 16 ) in this cohort showed significantly shorter progression-free survival associated with MYCN amplification TP53 mutation, LCA pathology, M+ disease, and R+ disease, but no associations with TERT mutation status or sex (table 2; appendix pp [18] [19] . Multivariate Cox modelling, showed that MYCN amplification, TP53 mutation, and M+ disease are independent risk factors for progression-free survival (table 2) . Only the 42 samples with complete clinical information for the considered variables were included. The disease-wide risk-stratification scheme currently in use for the HIT-SIOP-PNET5-MB clinical trial, 16 which deems MYCN amplification, LCA pathology, M+ disease, and R+ disease as high-risk factors, outperformed the MB SHH-Child subgroup stratification in AUC analysis (appendix pp [16] [17] . We used this HIT-SIOP-PNET5-MB stratification scheme as the basis of a combined risk-stratification model for MB SHH-Child (appendix pp [16] [17] , classifying patients with any one of these risk factors as very high risk. 50 patients had sufficient clinical data for classification using the scheme. This model discriminates favourable (24 [48%] of 50 patients, 5-year progression-free survival: 96% [95% CI 88-100]) and very high-risk (26 (52%), 5-year progression-free survival: 29% ) groups of patients within the MB SHH-Child subgroup (p<0·0001; appendix pp [16] [17] .
Combining all craniospinally irradiated patients in the MB Grp3/4 subgroup aged 3-16 years who had outcome data (n=175), allocation to the MB Grp3-HR and MB Grp4-HR subgroups was a significant high-risk factor for shorter progressionfree survival in univariate analysis (table 3) . Additionally, in multivariate analysis, MYC amplification was identified as an independently prognostic high-risk factor, and chromosome 13 loss was associated with an improved outcome (table 3) . Identification of prognostic survival markers in combined childhood non-MB SHH and non-MB WNT survival cohort (aged 3·0-16·0 years, receiving craniospinal irradiation, with survival information). p values from Cox proportional hazards analyses are shown. The characteristics of covariates selected in cross-validated multivariate models are also shown. The high-risk methylomic group comprised samples from both MB Grp3 and MB Grp4 , defined by the shared MB Grp3/4 metagene V1. HR=hazard ratio. MB=medulloblastoma. Grp3=group 3. Grp4=group 4. M+=metastatic disease. M-=non-metastatic disease. i17q=isochromosome 17q. LCA=large-cell anaplastic. R+=residual disease (subtotal surgical resection). R-=no residual disease (gross total resection). figure 4A ; appendix pp 20-21). 156 patients had information for chromosome 13 loss and MYC amplification, of which three were classed as unassignable because they were MB Grp4 with MYC amplification (appendix pp [20] [21] . This stratification scheme outperformed current riskstratification models ( figure 4B ).
For comparison, we developed equivalent separate survival stratification schemes for MB Grp3 and MB Grp4 (appendix pp [22] [23] . Risk factors identified were broadly consistent with the factors identified in the combined scheme, although the combined scheme was a better predictor of progression-free survival than when MB Grp3 and MB Grp4 were considered separately (figure 4B). Taking MB Grp4 patients in isolation, in univariate analysis, a designation of MB Grp4-HR , chromosome 7q status, M+ disease, and male sex were associated with poor progression-free survival, whereas MYCN amplification, R+ disease, and LCA pathology were not (appendix pp [22] [23] . Chromosome 7q gain and M+ disease were retained as independent prognostic factors in multivariate analysis (appendix pp [22] [23] Taking patients with MB Grp3 in isolation, MYC amplification was the only risk factor significantly associated with progression-free survival in multivariate analysis, and outcomes were poor for these very high-risk patients (appendix pp [22] [23] . Patients in the MB Grp3 with non-MYC amplified tumours were at high risk, with progression-free survival similar to that for the MB Grp4 1 were frequent in patients in MB Grp3 but none were associated with prognosis, and no stratification scheme based on MB Grp3 alone markedly improved outcome prediction compared with standard stratification schemes (appendix pp 22-23). 6 (9) 8 (34) 7 (36) 7 (8) 16 (26) 15 (29) 10 (5) 24 (18) 26 (23) 14 (2) 34 (11) 41 (19) 0 (2) 2 (13) The clinicopathological and molecular features of the new seven clinically significant subgroups are summarised in figure 5 . The combination of subgroupspecific survival models creates an overarching risk stratification for all childhood medulloblastoma (figure 6A figure 6B ). 215 patients aged 3-16 years at diagnosis had data available for these factors. The AUC from our proposed stratification of childhood medulloblastoma outperforms current and proposed cytogenetic risk stratifications ( figure 6C) . 28 We note that of 218 patients; figure 6A, C; appendix pp [24] [25] , which could be considered as an alternative stratification scheme. The proposed refinement to the stratification enables additional cases classified as MB Grp3-LR and MB Grp4-LR that do not have copy number information (other than MYC amplification status) and are nonmetastatic to be classified as favourable.
Discussion
The discovery and validation of seven robust and reproducible primary molecular subgroups of childhood medulloblastoma in this retrospective cohort study represents, to our knowledge, the first clinically significant elaboration of the four-subgroup consensus established in 2012. 1 While our work supports the stability of the four established groups, it also reveals significant substructures within each group with distinct clinicopathological and molecular features. Importantly, these primary subgroups emerge from unsupervised analysis, and are supported by distinguishing DNA methylation, gene expression, and copy-number profiles, consistent in discovery and validation cohorts. Notably, these subgroups were not identifiable in a previously published dataset, which included fewer samples and, specifically, fewer infant patients. 8 Our seven subgroups reveal a biological overlap between MB Grp3 and MB Grp4 . They share a biological signature, defined by a common metagene, indicating a clinicobiological overlap, which might suggest a common origin.
These primary subgroups may be further subdivided by the presence or absence of secondary molecular characteristics, many of which, in turn, have subgroupspecific clinical and prognostic significance (eg, MYC (26) 15 (29) 5 (7) 27 (24) 24 (18) 26 (23) 5 (7) 40 (14) 34 (11) amplification in MB Grp3 or TP53 mutation, MYCN amplification, LCA pathology, M+ disease, and R+ disease in MB SHH-Child ). Some of these secondary features have been described and assigned clinical significance in previous studies; in this Article, their association with specific novel subgroups (eg, chromosome 11 loss and chromosome 17 gain in MB ) has revealed the underlying biological basis of these subgroup-specific biomarkers. Moreover, re-evaluation of currently used high-risk factors derived from cohort-wide studies that did not consider subgroup shows that their importance is either low (eg, LCA pathology, M+ disease, or R+ disease in MB Grp3 ; MYCN in MB Grp4 ) or high (MYCN amplification, LCA pathology, TP53 mutation, and M+ disease in MB SHH-Child ; MYC in MB Grp3 ; M+ in MB Grp4 ) when considered in the context of our new subgroups. Finally, the biological definition of MB SHH-Infant (<4·3 years) is at odds with current clinical definitions of infant disease (<3 years) and this should prompt consideration in the future as to whether infant treatment protocols are appropriate for MB SHH-Infant patients older than 3 years. 16 Survival modelling in children younger than 3 years is qualitatively different from analysis in those over 3 years of age, because of the heterogeneity of treatment of infant disease. As such, we regarded further risk modelling in this patient group to be outside the scope of this study, to be addressed in future investigations. To our knowledge, no previous study has directly assessed survival of the molecularly-defined MB SHH-Infant subgroup. The overall survival at 5 years that we observed in MB SHH-Infant disease (62%, 95% CI 50-77) is lower than previously reported in an international meta-analysis of the MB SHH subgroup in age-defined infants (<4 years at diagnosis; 77%), 30 but these patients were not molecularly defined and, as such, are not directly comparable.
Our survival analysis focused on the 3-16-year-old clinical group who received current conventional therapies: surgical resection followed by adjuvant radiotherapy with or without chemotherapy at diagnosis with curative intent. Combined risk-modelling across all patients in the non-MB WNT or non-MB SHH subgroups identified MYC amplification, high-risk methylation subgroup membership, and loss of chromosome 13 as independent risk factors. Survival models incorporating these factors outperformed the clinical risk-stratification used in current clinical trials (HIT-SIOP-PNET5-MB 16 ) and subgroup-dependent cytogenetic stratification schemes. 28 We have defined a risk-stratification of childhood medulloblastoma that allows patients to be assigned into four overarching risk groups. Favourable-risk patients, including both MB WNT and novel non-MB WNT groups, should be urgently considered for therapy-reducing strategies. Very high-risk patients, typically refractory to conventional therapies (eg, amplified MYCN, mutated TP53, LCA pathology, and M+ disease in MB SHH and amplified MYC in MB Grp3 ) should be prioritised for alternative upfront treatment strategies. The priority for high-risk patients, comprising the novel MB Grp4-HR and patients with non-amplified MYC in the MB Grp3-HR subgroup, and a standard-risk group, comprising all other patients, should be optimisation of current therapies and the application of novel, biologically targeted agents.
We note the limitations of developing survival models in retrospective patient cohorts, who received heterogeneous treatments. Notwithstanding that models were developed using patients aged 3-16 years, who all received maximal surgical resection and craniospinal irradiation with curative intent, caution should be applied to their clinical implementation. We also note the statistical limitations of stratifications identifying small numbers of patients (eg, very highrisk, 13% of patients). Moreover, some of the identified biomarkers (notably loss of chromosome 13) have not previously been reported as prognostic. We therefore emphasise that validation in additional cohorts, and ideally in prospective, uniformly treated patients in clinical trials, is essential. A small number of samples (<5 samples) from this study were used to assist with the creation of the four-subgroup classification consensus. 5 Similarly, our own publication that described four methylation-dependent subgroups of medulloblastoma 7 contained 87 samples that overlapped with this study, although the previously published study contained fewer samples (discovery cohort size of 100 and validation cohort size of 130 patients) and DNA methylation profiling was at much lower resolution (1505 vs >400 000 CpG loci).
The existence of novel primary medulloblastoma subgroups, coupled with the characterisation of secondary prognostic features within each group, represents a significant advance in our understanding of medulloblastoma biology and its application in clinical management and future trials design. We provide clear evidence of the shared biology between MB Grp3 and MB Grp4 , which affects clinical behaviour and has significant implications for understanding disease biology, developmental origins, and experimental modelling. These investigations constitute a blueprint for a new consensus in medulloblastoma molecular subclassification with important implications for future molecular diagnostics and clinical management.
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